Novartis Investigative Site

Columbia, Maryland 21044

0 studies enrolling now · 17 studies all time

What they study most

Asthma, Atherosclerosis, Cancer, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Coronary Artery Disease (CAD), Coronary Atherosclerosis, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. — Completed
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone — Stopped early
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Efficacy and Safety Study of QVA149 in COPD Patients — Completed
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• 12-week Efficacy of Indacaterol — Completed